Market closed
Perspective Therapeutics/$CATX
Perspective Therapeutics shares are trading higher after the company provided recent business highlights and reported its Q1 2025 results.
15 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perspective Therapeutics
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Ticker
$CATX
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
139
ISIN
US46489V3024
CATX Metrics
BasicAdvanced
$186M
-
-$1.23
1.26
-
Price and volume
Market cap
$186M
Beta
1.26
52-week high
$19.05
52-week low
$1.60
Average daily volume
831K
Financial strength
Current ratio
12.68
Quick ratio
12.529
Long term debt to equity
1.05
Total debt to equity
1.397
Interest coverage (TTM)
-1,391.60%
Management effectiveness
Return on assets (TTM)
-19.02%
Return on equity (TTM)
-42.82%
Valuation
Price to revenue (TTM)
111.219
Price to book
0.61
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-2.224
Growth
Revenue change (TTM)
1.39%
Earnings per share change (TTM)
-29.18%
What the Analysts think about CATX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
CATX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CATX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CATX News
AllArticlesVideos
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
GlobeNewsWire·1 day ago
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
GlobeNewsWire·3 weeks ago
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Perspective Therapeutics stock?
Perspective Therapeutics (CATX) has a market cap of $186M as of May 14, 2025.
What is the P/E ratio for Perspective Therapeutics stock?
The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of May 14, 2025.
Does Perspective Therapeutics stock pay dividends?
No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Perspective Therapeutics dividend payment date?
Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.
What is the beta indicator for Perspective Therapeutics?
Perspective Therapeutics (CATX) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.